Chen, Fei, Zhang, Guo-Nan, Lei, Wei, Zhou, Shu-Guang, Zhang, Ying, Liu, Lin, Jia, Ying, Xie, Rong-Kai, Tian, Xiu-Fang, Guo, Jie, Yang, Yue-Bo, Wang, Xue-Feng, Wu, Xiao-Mei, Sun, Qi-Jian, Zhou, Xu, Lin, Yang, Zhang, You-Zhong, Ma, Jun-Qi, Liu, Yu-Xiu, and Cheng, Yi-Fan
We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient's age. According to inclusion/exclusion criteria and participant willingness, 3252 patients were divided into REBACIN group while 249 patients into control group. Patients in REBACIN group received one course treatment of intravaginal administration of REBACIN while no treatment in control group. After drug withdrawal, participants in both groups were followed up. The clearance rate of persistent hrHPV infection in REBACIN group was 60.64%, compared to 20.08% in control group. Specifically, the clearance rates for single-type infection of HPV16 or HPV18 were 70.62% and 69.23%, respectively, which was higher than that of HPV52 (59.04%) or HPV58 (62.64%). In addition, the single, double, and triple/triple+ infections had a clearance rate of 65.70%, 53.31%, and 38.30%, respectively. Moreover, 1635 patients under 40 years old had a clearance rate of 65.14%, while it was 55.08% for 1447 patients over 40 years old. No serious adverse effects were found. This study confirmed that REBACIN can effectively and safely eliminate persistent hrHPV infection, which the clearance rate of HPV16/18 is higher than that of HPV52/58, the clearance rate of single-type infection is higher than that of multiple-type infections, and the clearance rate in young patients is higher than that in elder patients, providing a guidance for REBACIN application in clearing hrHPV persistent infection in real-world settings. Chinese Clinical Trial Registry Registration Number: ChiCTR1800015617 http://www.chictr.org.cn/showproj.aspx?proj=26529 Date of Registration: 2018-04-11 • REBACIN is safe and effective for eliminating persistent high-risk HPV infection in a real-world clinical setting. • HPV16/18 is cleared more easily than HPV52/58. • Single-type infections are cleared more easily than multiple-type infections. • Young patients have a higher clearance rate than older patients. • Providing valuable guidance for clinical use of REBACIN while also suggesting potential areas for future basic research. [ABSTRACT FROM AUTHOR]